

Rish K Pai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3684781/publications.pdf>

Version: 2024-02-01

159
papers

6,104
citations

81900

39
h-index

88630

70
g-index

161
all docs

161
docs citations

161
times ranked

8176
citing authors

#	ARTICLE	IF	CITATIONS
1	International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease. <i>Gut</i> , 2022, 71, 479-486.	12.1	29
2	Utilizing Deep Learning to Analyze Whole Slide Images of Colonic Biopsies for Associations Between Eosinophil Density and Clinicopathologic Features in Active Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 539-546.	1.9	15
3	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 659-670.	2.9	40
4	Gastrointestinal stromal tumors (GISTs) arising in uncommon locations: clinicopathologic features and risk assessment of esophageal, colonic, and appendiceal GISTs. <i>Modern Pathology</i> , 2022, 35, 554-563.	5.5	9
5	Measuring Histologic Activity in Inflammatory Bowel Disease: Why and How. <i>Advances in Anatomic Pathology</i> , 2022, 29, 37-47.	4.3	8
6	Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2022, 117, 264-271.	0.4	13
7	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.	2.3	4
8	Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1 α stabiliser, for treatment of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 401-411.	3.7	18
9	Associations Between Glycemic Traits and Colorectal Cancer: A Mendelian Randomization Analysis. <i>Journal of the National Cancer Institute</i> , 2022, 114, 740-752.	6.3	35
10	Genome-wide association study identifies tumor anatomical site-specific risk variants for colorectal cancer survival. <i>Scientific Reports</i> , 2022, 12, 127.	3.3	6
11	Genetic variants associated with circulating C-reactive protein levels and colorectal cancer survival: Sex-specific and lifestyle factors specific associations. <i>International Journal of Cancer</i> , 2022, 150, 1447-1454.	5.1	2
12	Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study. <i>Journal of the National Cancer Institute</i> , 2022, , .	6.3	15
13	Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis. <i>PLoS Medicine</i> , 2022, 19, e1003897.	8.4	30
14	The Clinical Significance of Eosinophils in Ulcerative Colitis: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1321-1334.	1.3	4
15	Editorial: protecting hypoxia-inducible factor 1 α and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 735-736.	3.7	0
16	Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis. , 2022, 10, e004560.		9
17	Large-scale Integrated Analysis of Genetics and Metabolomic Data Reveals Potential Links Between Lipids and Colorectal Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1216-1226.	2.5	3
18	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	7.3	15

#	ARTICLE	IF	CITATIONS
19	Subtyping intestinal metaplasia in patients with chronic atrophic gastritis: an interobserver variability study. <i>Pathology</i> , 2022, 54, 262-268.	0.6	5
20	Practical Updates in the Pathology of Inflammatory Bowel Disease. <i>Advances in Anatomic Pathology</i> , 2022, 29, 1-1.	4.3	2
21	Interobserver agreement of estimating the extent of intestinal metaplasia in patients with chronic atrophic gastritis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1277-1281.	2.8	1
22	Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1077-1089.	2.5	6
23	Genetic Regulation of DNA Methylation Yields Novel Discoveries in GWAS of Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1068-1076.	2.5	1
24	Development and Validation of a Digital Analysis Method to Quantify CD3-immunostained T Lymphocytes in Whole Slide Images of Crohn's Disease Biopsies. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, Publish Ahead of Print, .	1.2	0
25	Image Analysis of Eosinophil Peroxidase Immunohistochemistry for Diagnosis of Eosinophilic Esophagitis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 775-783.	2.3	16
26	Non-conventional dysplasias of the tubular gut: a review and illustration of their histomorphological spectrum. <i>Histopathology</i> , 2021, 78, 658-675.	2.9	17
27	Reduced MFAP5 expression in stroma of gallbladder adenocarcinoma and its potential diagnostic utility. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 427-434.	2.8	1
28	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 784-793.	3.7	18
29	Rare Variants in the DNA Repair Pathway and the Risk of Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 895-903.	2.5	3
30	Mesenteric and Retroperitoneal Mucinous Cystic Neoplasms: A Case Series. <i>International Journal of Surgical Pathology</i> , 2021, 29, 606-614.	0.8	1
31	Validated Indices for Histopathologic Activity Predict Development of Colorectal Neoplasia in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1481-1490.	1.3	3
32	Assessment of a Polygenic Risk Score for Colorectal Cancer to Predict Risk of Lynch Syndrome Colorectal Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab022.	2.9	15
33	Development and initial validation of a deep learning algorithm to quantify histological features in colorectal carcinoma including tumour budding/poorly differentiated clusters. <i>Histopathology</i> , 2021, 79, 391-405.	2.9	24
34	Nongenetic Determinants of Risk for Early-Onset Colorectal Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab029.	2.9	39
35	Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1349-1358.	2.5	6
36	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. <i>Gastroenterology</i> , 2021, 160, 2291-2302.	1.3	57

#	ARTICLE	IF	CITATIONS
37	Upper Gastrointestinal Tract Involvement in Inflammatory Bowel Diseases. <i>Advances in Anatomic Pathology</i> , 2021, Publish Ahead of Print, 2-14.	4.3	8
38	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 1014-1022.	10.7	58
39	DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. , 2021, 9, e002671.		37
40	A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. <i>Gastroenterology</i> , 2021, 161, 778-784.	1.3	0
41	A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients. <i>European Journal of Cancer</i> , 2021, 159, 247-258.	2.8	6
42	The significance of histological activity measurements in immune checkpoint inhibitor colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 150-159.	3.7	12
43	Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapyâ€checkpoint inhibitory colitis. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 638-639.	3.7	0
44	Editorial: an expert consensus to standardise the assessment of histological disease activity in Crohnâ€™s disease clinical trialsâ€™a missing link. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 952-952.	3.7	0
45	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1108-1117.	3.7	13
46	Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohnâ€™s Disease: A Systematic Review. <i>Gastroenterology</i> , 2020, 158, 137-150.e1.	1.3	50
47	Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2510-2517.e5.	4.4	46
48	Clinical and histological features of secondary carcinomas in gastrointestinal tract biopsies. <i>Histopathology</i> , 2020, 77, 622-630.	2.9	4
49	Smooth muscle tumors of the gastrointestinal tract: an analysis of prognostic features in 407 cases. <i>Modern Pathology</i> , 2020, 33, 1410-1419.	5.5	13
50	Editorial: histologic normalisation in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 399-401.	3.7	1
51	Detection of DNA mismatch repair deficient crypts in random colonoscopic biopsies identifies Lynch syndrome patients. <i>Familial Cancer</i> , 2020, 19, 169-175.	1.9	16
52	Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1574-1582.	3.7	5
53	Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. <i>Cut</i> , 2019, 68, 1162-1168.	12.1	45
54	Comparison of narrow-band imaging, volumetric laser endomicroscopy, and pathologic findings in Barrett's esophagus. <i>VideoGIE</i> , 2019, 4, 319-322.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Editorial: evolving histological assessment of NASH. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1245-1246.	3.7	0
56	NAFLD Histology: a Critical Review and Comparison of Scoring Systems. <i>Current Hepatology Reports</i> , 2019, 18, 473-481.	0.9	8
57	Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1100-1111.	3.7	27
58	Gastrointestinal Mastocytosis: A Potential Diagnostic Pitfall to Be Aware. <i>International Journal of Surgical Pathology</i> , 2019, 27, 643-646.	0.8	5
59	Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1401-1409.	3.7	21
60	An update on the morphology and molecular pathology of serrated colorectal polyps and associated carcinomas. <i>Modern Pathology</i> , 2019, 32, 1390-1415.	5.5	73
61	What is the role of histopathology in the evaluation of disease activity in Crohn's disease?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101601.	2.4	11
62	Gene Expression Changes Accompanying the Duodenal Adenoma-Carcinoma Sequence in Familial Adenomatous Polyposis. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00053.	2.5	10
63	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , 2019, 114, 733-745.	0.4	42
64	Definitions of response and remission for the Robarts Histopathology Index. <i>Gut</i> , 2019, 68, 2101-2102.	12.1	29
65	Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer. <i>Annals of Surgery</i> , 2019, 269, 1117-1123.	4.2	49
66	Colorectal Serrated Polyp With Stromal Changes: An Interobserver Agreement Study. <i>Gastroenterology Research</i> , 2019, 12, 299-304.	1.3	1
67	Reliability of histologic assessment in patients with eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 940-950.	3.7	51
68	Novel Computer-enhanced Visualization of Volumetric Laser Endomicroscopy Correlates Endoscopic and Pathological Images. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, A23-A24.	4.4	6
69	Colorectal Carcinomas With Isolated Loss of PMS2 Staining by Immunohistochemistry. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 523-528.	2.5	22
70	Gastric pyloric gland adenoma: a multicentre clinicopathological study of 67 cases. <i>Histopathology</i> , 2018, 72, 1007-1014.	2.9	33
71	Substantial Interobserver Agreement in the Diagnosis of Dysplasia in Barrett Esophagus Upon Review of a Patient's Entire Set of Biopsies. <i>American Journal of Surgical Pathology</i> , 2018, 42, 376-381.	3.7	11
72	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1578-1596.	3.7	31

#	ARTICLE	IF	CITATIONS
73	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1407-1419.e22.	4.4	41
74	Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 99-110.	2.8	35
75	Centrilobular ductular reaction correlates with fibrosis stage and fibrosis progression in non-alcoholic steatohepatitis. <i>Modern Pathology</i> , 2018, 31, 150-159.	5.5	26
76	Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy. <i>Modern Pathology</i> , 2018, 31, 4-23.	5.5	31
77	The emerging role of histologic disease activity assessment in ulcerative colitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 887-898.	1.0	93
78	Small Intestine Neuroendocrine Tumor in a Patient With MUTYH Adenomatous Polyposis: Case Report and SEER Analysis. <i>Clinical Colorectal Cancer</i> , 2018, 17, e545-e548.	2.3	3
79	Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1714-1729.e3.	4.4	33
80	Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (<sc>EOE</sc> and <sc>HSS</sc>) as an important first step. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1714-1715.	3.7	2
81	DNA mismatch repair protein deficient non-neoplastic colonic crypts: a novel indicator of Lynch syndrome. <i>Modern Pathology</i> , 2018, 31, 1608-1618.	5.5	32
82	Development and validation of a histological index for UC. <i>Gut</i> , 2017, 66, 50-58.	12.1	264
83	Biopsy Specimens From Allograft Liver Contain Histologic Features of Hepatitis C Virus Infection After Virus Eradication. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1279-1285.	4.4	30
84	Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild to moderate ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 292-302.	3.7	29
85	Colorectal carcinomas with submucosal invasion (pT1): analysis of histopathological and molecular factors predicting lymph node metastasis. <i>Modern Pathology</i> , 2017, 30, 113-122.	5.5	29
86	A Practical Approach to the Evaluation of Gastrointestinal Tract Carcinomas for Lynch Syndrome. <i>American Journal of Surgical Pathology</i> , 2016, 40, e17-e34.	3.7	48
87	Gastric bypass surgery is protective from high-fat diet-induced non-alcoholic fatty liver disease and hepatic endoplasmic reticulum stress. <i>Acta Physiologica</i> , 2016, 217, 141-151.	3.8	29
88	Expression of Annexin A10 in Serrated Polyps Predicts the Development of Metachronous Serrated Polyps. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e205.	2.5	16
89	Sonic hedgehog signaling in hepatocellular carcinoma: A pilot study. <i>Molecular and Clinical Oncology</i> , 2016, 4, 369-374.	1.0	21
90	The Significance of Sessile Serrated Polyps in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2213-2220.	1.9	25

#	ARTICLE	IF	CITATIONS
91	Prevalence of <i>Helicobacter pylori</i> in Gastric Hyperplastic Polyps. International Journal of Surgical Pathology, 2016, 24, 704-708.	0.8	41
92	Interobserver variability in intraductal papillary mucinous neoplasm subtypes and application of their mucin immunoprofiles. Modern Pathology, 2016, 29, 977-984.	5.5	13
93	NPTX2 is associated with neoadjuvant therapy response in rectal cancer. Journal of Surgical Research, 2016, 202, 112-117.	1.6	14
94	Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS5745 versus placebo for ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2016, 44, 157-169.	3.7	53
95	Gastric Proteins MUC5AC and TFF1 as Potential Diagnostic Markers of Colonic Sessile Serrated Adenomas/Polyps. American Journal of Clinical Pathology, 2016, 146, 530-537.	0.7	18
96	The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 995-1000.	2.8	19
97	Abrupt Loss of MLH1 and PMS2 Expression in Endometrial Carcinoma. American Journal of Surgical Pathology, 2015, 39, 993-999.	3.7	41
98	Risk of Metachronous Polyps in Individuals With Serrated Polyps. Diseases of the Colon and Rectum, 2015, 58, 762-768.	1.3	43
99	Traditional serrated adenoma: An enigmatic and aggressive polyp?. Gastrointestinal Endoscopy, 2015, 82, 1094-1096.	1.0	0
100	Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clinical, 2015, 3, 141-145.	4.1	53
101	Assessment of a novel, full-thickness incisional biopsy model to restage rectal tumours after neoadjuvant chemoradiotherapy: results of an ex vivo pilot study. Techniques in Coloproctology, 2015, 19, 159-164.	1.8	13
102	IgG4-related sclerosing cholangitis in the absence of autoimmune pancreatitis mimicking extrahepatic cholangiocarcinoma. Scandinavian Journal of Gastroenterology, 2015, 50, 447-453.	1.5	18
103	Age Impacts Ability of Aspartate/Alanine Aminotransferase Ratio to Predict Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2015, 60, 1825-1831.	2.3	18
104	Gastric Polyposis: A Rare Cause of Iron Deficiency Anemia in a Patient With Portal Hypertension. ACG Case Reports Journal, 2015, 2, 89-91.	0.4	4
105	Reproducibility of histological assessments of disease activity in UC. Gut, 2015, 64, 1765-1773.	12.1	66
106	Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 262-267.	2.8	26
107	Risk for Colorectal Neoplasia in Patients with Inflammatory Bowel Disease and Mucosa Indefinite for Dysplasia. Inflammatory Bowel Diseases, 2015, 21, 378-384.	1.9	30
108	American Joint Committee on Cancer and College of American Pathologists Regression Grade. Diseases of the Colon and Rectum, 2015, 58, 32-44.	1.3	124

#	ARTICLE	IF	CITATIONS
109	Response to: Laboratory assessment may be dependent on the time of liver biopsy. <i>Liver International</i> , 2015, 35, 287-288.	3.9	0
110	Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. <i>Liver International</i> , 2015, 35, 979-985.	3.9	87
111	Diagnostic utility of TP53 and cytokeratin 7 immunohistochemistry in idiopathic inflammatory bowel disease-associated neoplasia. <i>Modern Pathology</i> , 2014, 27, 303-313.	5.5	55
112	Depth and lateral spread of microscopic residual rectal cancer after neoadjuvant chemoradiation: implications for treatment decisions. <i>Colorectal Disease</i> , 2014, 16, 610-615.	1.4	29
113	Sebaceous Hyperplasia of the Vulva. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 437-442.	1.4	7
114	Morphologic and Molecular Characterization of Traditional Serrated Adenomas of the Distal Colon and Rectum. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1290-1297.	3.7	60
115	Immunohistochemistry for Annexin A10 Can Distinguish Sporadic From Lynch Syndrome-associated Microsatellite-unstable Colorectal Carcinoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 518-525.	3.7	14
116	Clinical Criteria Underestimate Complete Pathological Response in Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 311-315.	1.3	127
117	Serrated lesions of the appendix frequently harbor KRAS mutations and not BRAF mutations indicating a distinctly different serrated neoplastic pathway in the appendix. <i>Human Pathology</i> , 2014, 45, 227-235.	2.0	55
118	Benign and malignant tumors of the rectum and perirectal region. <i>Abdominal Imaging</i> , 2014, 39, 824-852.	2.0	24
119	A practical approach to small bowel biopsy interpretation: Celiac disease and its mimics. <i>Seminars in Diagnostic Pathology</i> , 2014, 31, 124-136.	1.5	21
120	Re-examination of sinusoidal deposition of complement 4d in liver allografts: experience from a single institution. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 784-91.	0.5	3
121	Gene expression profiling of serrated polyps identifies annexin A10 as a marker of a sessile serrated adenoma/polyp. <i>Journal of Pathology</i> , 2013, 230, 420-429.	4.5	67
122	Implementation of Universal Microsatellite Instability and Immunohistochemistry Screening for Diagnosing Lynch Syndrome in a Large Academic Medical Center. <i>Journal of Clinical Oncology</i> , 2013, 31, 1336-1340.	1.6	147
123	Tu1490 Patients With Adenomatous and Serrated Polyps Warrant Closer Surveillance Than Patients With Adenomas Only. <i>Gastrointestinal Endoscopy</i> , 2013, 77, AB559.	1.0	1
124	Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. <i>Journal of Experimental Medicine</i> , 2013, 210, 2851-2872.	8.5	288
125	Semiquantitative histologic evaluation improves diagnosis of esophageal carcinoma cuniculatum on biopsy. <i>Modern Pathology</i> , 2013, 26, 806-815.	5.5	17
126	Statin Therapy Is Associated With Improved Pathologic Response to Neoadjuvant Chemoradiation in Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 1217-1227.	1.3	61

#	ARTICLE	IF	CITATIONS
127	Reproducibility of the Villous Component and High-grade Dysplasia in Colorectal Adenomas <1 cm. American Journal of Surgical Pathology, 2013, 37, 427-433.	3.7	40
128	Hepatocellular carcinoma complicating recurrent hepatitis C after liver transplantation. Hepatology, 2013, 58, 1854-1855.	7.3	0
129	Paneth Cells in Colonic Adenomas. American Journal of Surgical Pathology, 2013, 37, 98-103.	3.7	19
130	Proximal colon cancers and the serrated pathway: a systematic analysis of precursor histology and BRAF mutation status. Modern Pathology, 2012, 25, 1423-1431.	5.5	42
131	Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leukemia and Lymphoma, 2012, 53, 1552-1557.	1.3	27
132	Pulmonary Tumor Thrombotic Microangiopathy in Patients With Low-grade Ovarian Serous Neoplasm. International Journal of Gynecological Pathology, 2012, 31, 438-442.	1.4	13
133	Distinct Clinicohistologic Features of Inflammatory Bowel Disease-associated Colorectal Adenocarcinoma. American Journal of Surgical Pathology, 2012, 36, 1228-1233.	3.7	79
134	BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon. American Journal of Surgical Pathology, 2012, 36, 744-752.	3.7	161
135	Hepatic angiosarcoma mimicking sinusoidal obstruction syndrome/venoocclusive disease: a pathologic-radiologic correlation. Annals of Diagnostic Pathology, 2012, 16, 275-279.	1.3	6
136	Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Modern Pathology, 2012, 25, 1128-1139.	5.5	250
137	Sessile serrated polyps: Cancer risk and appropriate surveillance. Cleveland Clinic Journal of Medicine, 2012, 79, 865-871.	1.3	13
138	Pattern of Lymph Node Involvement and Prognosis in Pancreatic Adenocarcinoma. American Journal of Surgical Pathology, 2011, 35, 228-234.	3.7	36
139	Histologic and Molecular Analyses of Colonic Perineurial-like Proliferations in Serrated Polyps. American Journal of Surgical Pathology, 2011, 35, 1373-1380.	3.7	32
140	Sarcina Organisms in the Gastrointestinal Tract. American Journal of Surgical Pathology, 2011, 35, 1700-1705.	3.7	90
141	Esophageal disease and pathology. Annals of the New York Academy of Sciences, 2011, 1232, 376-380.	3.8	1
142	PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Modern Pathology, 2011, 24, 412-424.	5.5	115
143	Identification of Histologically Distinct Conventional Adenomas that Arise Predominately in Patients With Sessile Serrated Adenomas. American Journal of Surgical Pathology, 2010, 34, 355-363.	3.7	30
144	Sessile serrated adenomas strongly predispose to synchronous serrated polyps in non-syndromic patients. Histopathology, 2010, 56, 581-588.	2.9	59

#	ARTICLE	IF	CITATIONS
145	Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. <i>Leukemia and Lymphoma</i> , 2010, 51, 2240-2249.	1.3	40
146	Aberrant expression of cytokeratin 7 in perivenular hepatocytes correlates with a cholestatic chemistry profile in patients with heart failure. <i>Modern Pathology</i> , 2010, 23, 1650-1656.	5.5	24
147	Molecular Testing in Colorectal Carcinoma. <i>Surgical Pathology Clinics</i> , 2010, 3, 429-445.	1.7	1
148	Successful Nonoperative Management of Gastrointestinal Mucormycosis: Novel Therapy for Invasive Disease. <i>Surgical Infections</i> , 2009, 10, 447-451.	1.4	22
149	Marked Flare in Hepatic Aminotransferases During Treatment with Pegylated Interferon for Chronic Hepatitis C, Genotype 2: A Case Report. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1369-1372.	2.3	2
150	Successful palliation of hypercalcemia secondary to metastatic parathyroid cancer: an unusual indication for hepatic resection. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2007, 14, 410-413.	2.0	12
151	<i>Mycobacterium tuberculosis</i> 19-kDa Lipoprotein Inhibits IFN- γ -Induced Chromatin Remodeling of MHC2TA by TLR2 and MAPK Signaling. <i>Journal of Immunology</i> , 2006, 176, 4323-4330.	0.8	198
152	Prolonged Toll-Like Receptor Signaling by <i>Mycobacterium tuberculosis</i> and Its 19-Kilodalton Lipoprotein Inhibits Gamma Interferon-Induced Regulation of Selected Genes in Macrophages. <i>Infection and Immunity</i> , 2004, 72, 6603-6614.	2.2	150
153	Inhibition of Major Histocompatibility Complex II Expression and Antigen Processing in Murine Alveolar Macrophages by <i>Mycobacterium bovis</i> BCG and the 19-Kilodalton <i>Mycobacterium</i> Lipoprotein. <i>Infection and Immunity</i> , 2004, 72, 2101-2110.	2.2	100
154	CpG DNA Induces a Class II Transactivator-Independent Increase in Class II MHC by Stabilizing Class II MHC mRNA in B Lymphocytes. <i>Journal of Immunology</i> , 2003, 171, 2320-2325.	0.8	14
155	Alternate Class I MHC Antigen Processing Is Inhibited by Toll-Like Receptor Signaling Pathogen-Associated Molecular Patterns: <i>Mycobacterium tuberculosis</i> 19-kDa Lipoprotein, CpG DNA, and Lipopolysaccharide. <i>Journal of Immunology</i> , 2003, 171, 1413-1422.	0.8	83
156	Inhibition of IFN- γ -Induced Class II Transactivator Expression by a 19-kDa Lipoprotein from <i>Mycobacterium tuberculosis</i> : A Potential Mechanism for Immune Evasion. <i>Journal of Immunology</i> , 2003, 171, 175-184.	0.8	226
157	Regulation of Class II MHC Expression in APCs: Roles of Types I, III, and IV Class II Transactivator. <i>Journal of Immunology</i> , 2002, 169, 1326-1333.	0.8	85
158	<i>Mycobacterium tuberculosis</i> 19-kDa Lipoprotein Promotes Neutrophil Activation. <i>Journal of Immunology</i> , 2001, 167, 1542-1549.	0.8	78
159	Toll-Like Receptor 2-Dependent Inhibition of Macrophage Class II MHC Expression and Antigen Processing by 19-kDa Lipoprotein of <i>Mycobacterium tuberculosis</i> . <i>Journal of Immunology</i> , 2001, 167, 910-918.	0.8	391